Zoster vaccine

Herpes zoster is a common condition especially in our aging cohort.  There is limited information about the use of HZ vaccine in this group.  Paper 96 presented results from a randomised, double-blind, placebo-controlled trial assessing safety and immunogenicity of 2 doses of ZV in HIV⁺ adults ≥18 years old (CD4 >200 copies/µL; HIV RNA  Preliminary data suggest that the vaccine is generally safe, and immunogenic. Further data from this study is awaited.